Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.03 USD
Change Today -0.02 / -0.98%
Volume 3.8K
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Thomas O. Daniel M.D.

President of Research & Early Development and Executive Vice President, Celgene Corporation
AgeTotal Calculated CompensationThis person is connected to 28 board members in 2 different organizations across 6 different industries.

See Board Relationships
61$7,670,580
As of Fiscal Year 2014

Background*

Dr. Thomas O. Daniel, M.D., has been the President of Research & Early development of Celgene Corporation since December 2006 and also served as its Executive Vice President since February 15, 2012. Dr. Daniel has more than two decades of medical and pharmaceutical research experience and served as the Chief Scientific Officer at Ambrx Inc. since September 2003. He served as the Vice President of Research at Amgen Inc., where he served as Research Site Head of Amgen ...

Read Full Background

Corporate Headquarters*

86 Morris Avenue
Summit, New Jersey 07901

United States

Phone: 908-673-9000
Fax: --

Board Members Memberships*

Director
2012-2014
Former Director

Education*

MD
University of Texas Southwestern Medical Center - Dallas

Other Affiliations*

Annual Compensation*

Salary$691,500
Total Annual Compensation$691,500

Stock Options*

Restricted Stock Awards$767,672
All Other Compensation$148,364
Exercised Options123,072
Exercised Options Value$8,196,733
Exercisable Options149,248
Unexercisable Options197,087
Total Value of Options$8,196,733
Total Number of Options469,407

Total Compensation*

Total Annual Cash Compensation$4,981,584
Total Short Term Compensation$691,500
Other Long Term Compensation$916,036
Total Calculated Compensation$7,670,580
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CELGZ:US $2.03 USD -0.02

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Giovanni Caforio M.D.Chief Executive Officer and Director
Bristol-Myers Squibb Company
$916.0K
George A. Scangos Ph.D.Chief Executive Officer and Director
Biogen Inc.
$1.4M
Brenton L. Saunders J.D.Chief Executive Officer, President and Director
Allergan plc
$500.0K
John C. Lechleiter Ph.D.Chairman, Chief Executive Officer and President
Eli Lilly and Company
$1.5M
J. Michael Pearson Chairman and Chief Executive Officer
Valeant Pharmaceuticals International, Inc.
$1.9M
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELGENE CORP-CVR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.